EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)

Florian Rosar, Joelle Schuler, Caroline Burgard, Arne Blickle, Mark Bartholomä, Stephan Maus, Sven Petto, Fadi Khreish, Andrea Schaefer, Samer Ezziddin iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-024-06825-4 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Florian Rosar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany. Hauptthemen laut MEDLINE: Dipeptides, Heterocyclic Compounds, 1-Ring, Lutetium, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Rechallenge of [ 177 Lu]Lu-PSMA-617 radioligand therapy (RLT) was proposed for patients who initially responded to PSMA-RLT experiencing partial remission, but relapsed into progression after a certain period of remission. However, only limited data is available regarding this approach. In this study, we analyzed the efficacy and safety profile of one or more series of [ 177 Lu]Lu-PSMA-617 RLT rechallenge in patients from a prospective registry (REALITY Study, NCT 04833517) after they initially benefited from PSMA-RLT.

Methods

Forty-seven patients with metastatic castration-resistant prostate cancer (mCRPC) who had biochemical response to initial [ 177 Lu]Lu-PSMA-617 RLT followed by disease progression received at least one (up to three) series of [ 177 Lu]Lu-PSMA-617 RLT rechallenge. Biochemical response rates based on prostate-specific antigen (PSA) serum value, PSA-based progression-free survival (PFS) and overall survival (OS) were calculated. Adverse events of the treatment were assessed according to ‘ common terminology criteria for adverse events ’ (CTCAE).

Results

After one series of RLT rechallenge, a PSA decline of at least 50% was achieved in 27/47 patients (57.4%). The median PFS of all patients was 8.7 mo and the median OS was 22.7 mo, each calculated from the administration of the first rechallenge series. Patients who responded (PSA decline > 50%) to the rechallenge showed a median OS of 27.3 mo. Regarding PFS, a significant correlation ( r = 0.4128, p = 0.0323) was found for these patients comparing initial and rechallenge RLT. Ten patients received a second and 3 patients received a third rechallenge series with 8/10 and 3/3 patients responding to repeated RLT rechallenge. No severe deterioration of adverse events rated by CTCAE criteria was observed. Conclusion [ 177 Lu]Lu-PSMA-617 RLT rechallenge is associated with significant PSA response and encouraging survival outcome as well as a very favourable safety profile and should therefore be considered as a straight-forward treatment option in mCRPC patients, who previously benefited from PSMA-RLT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overHumansMaleMiddle AgedProspective StudiesProstate-Specific AntigenRadiopharmaceuticalsRegistriesRemission InductionTreatment Outcome

Stichwörter der Autor:innen

177LuPSMARadioligand therapyRechallengemCRPC

Substanzen

DipeptidesHeterocyclic Compounds, 1-RingLutetiumPluvictoProstate-Specific AntigenPSMA-617Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
  • Department of Nuclear Medicine, Campus-Fulda, University of Marburg, Fulda, Germany.
  • Department of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany. samer.ezziddin@uks.eu.

ORCID-Profile: Samer Ezziddin

Förderung

  • Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes

Zitieren

APA

Rosar, F., Schuler, J., Burgard, C., Blickle, A., Bartholomä, M., Maus, S., Petto, S., Khreish, F., Schaefer, A., & Ezziddin, S. (2024). Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study). European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06825-4

Vancouver

Rosar F, Schuler J, Burgard C, Blickle A, Bartholomä M, Maus S, et al. Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study). European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06825-4

BibTeX
@article{Rosar2024,
  author = {Rosar, Florian and Schuler, Joelle and Burgard, Caroline and Blickle, Arne and Bartholomä, Mark and Maus, Stephan and Petto, Sven and Khreish, Fadi and Schaefer, Andrea and Ezziddin, Samer},
  title = {Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-024-06825-4}
}
Kostenlos starten →